Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...
Samsung Bioepis collaborates with Teva to launch Epysylli in U.S. market Samsung Bioepis and Teva join forces to introduce a ...
Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...
Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, manufacture and supply of the product, while Teva will be responsible for ...
Samsung Biologics has made history by becoming the nation's first biotech company to hit 4 trillion won ($2.78 billion) in ...
INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released its First Quarter 2025 Biosimilar Market Report, marking the eighth edition of the Quarterly Biosimilar ...
New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.
Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...
INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback